Share

Bain Capital’s $3.12bn private equity deal with Evident was the medical devices industry’s biggest cross border deal of Q3 2022 as cross border deals worth $8.1bn were announced globally in the quarter, according to GlobalData’s deals database.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked an increase of 11.9% over the previous quarter and a drop of 32.6% when compared with the last four-quarter average of $11.97bn.

In terms of number of cross border deals, the sector saw a drop of 26.90% with 144 deals in Q3 2022 against the average of 197.00 deals in the last four-quarters.

In value terms, Europe led the activity with cross border deals worth $3.26bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

medical devices industry cross border deals in Q3 2022: Top deals

The top five medical devices industry cross border deals accounted for 69.4% of the overall value during Q3 2022.

The combined value of the top five cross border deals stood at $5.59bn, against the overall value of $8.1bn recorded for the quarter.

The top five medical devices industry cross border deals of Q3 2022 tracked by GlobalData were:

1) Bain Capital’s $3.12bn private equity deal with Evident

2) The $1.54bn private equity of Meridian Bioscience by SD Biosensor and SJL Partners

3) Azenta’s $468.22m acquisition deal with B Medical Systems

4) The $243.32m acquisition of Medi-Globe by DCC Healthcare

5) Breyer Capital, Cigna Ventures, DigiTx Partners, Fidelity Management & Research, Heartland Healthcare Capital, LRVHealth, Mirae Asset Capital, New Leaf Ventures, Novartis, Peter Thiel, Piper Sandler Merchant Banking, Sands Capital Management, T Rowe Price Associates, T. Rowe Price Investment Management and Vensana Capital’s $223m venture financing deal with Cleerly